m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00180)
Target Name Transcription factor AP-2 gamma (TFAP2C)
Synonyms
AP2-gamma; Activating enhancer-binding protein 2 gamma; Transcription factor ERF-1
    Click to Show/Hide
Gene Name TFAP2C
Chromosomal Location 20q13.31
Family AP-2 family
Function
Sequence-specific DNA-binding protein that interacts with inducible viral and cellular enhancer elements to regulate transcription of selected genes. AP-2 factors bind to the consensus sequence 5'-GCCNNNGGC-3' and activate genes involved in a large spectrum of important biological functions including proper eye, face, body wall, limb and neural tube development. They also suppress a number of genes including MCAM/MUC18, C/EBP alpha and MYC. Involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer.
    Click to Show/Hide
Gene ID 7022
Uniprot ID
AP2C_HUMAN
HGNC ID
HGNC:11744
Ensembl Gene ID
ENSG00000087510
KEGG ID
hsa:7022
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
TFAP2C can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Methyltransferase-like 3 (METTL3) [WRITER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by METTL3
Cell Line Embryonic stem cells Mus musculus
Treatment: METTL3-/- mESCs
Control: Wild type ESCs
 GSE147849
Regulation
logFC: 1.20E+00
p-value: 4.47E-08
More Results Click to View More RNA-seq Results
Representative RIP-seq result supporting the interaction between TFAP2C and the regulator
Cell Line MDA-MB-231 Homo sapiens
Regulation logFC: 2.28E+00 GSE60213
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary METTL3 potentiates resistance to cisplatin through m6A modification of Transcription factor AP-2 gamma (TFAP2C) in seminoma. Enhanced stability of TFAP2C mRNA promoted seminoma cell survival under cisplatin treatment burden probably through up-regulation of DNA repair-related genes. IGF2BP1 binds to TFAP2C and enhances TFAP2C mRNA stability.
Target Regulation Up regulation
Responsed Disease Testicular cancer ICD-11: 2C80
 Disease Info 
Responsed Drug Cisplatin Approved
 Drug Info 
Pathway Response Nucleotide excision repair hsa03420
Cell Process DNA repair
In-vitro Model TCam-2 Testicular seminoma Homo sapiens CVCL_T012
In-vivo Model Male mice were subcutaneously injected with tumour cells near the limbs to establish xenografts (1 × 106/mouse, 0.2 mL for each injection site; METTL3-overexpressing TCam-2/CDDP cells were inoculated once at the initial time and IGF2BP1-inhibited TCam-2/CDDP cells were inoculated every 3 days).
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) [READER]
 Regulator Info 
Representative RNA-seq result indicating the expression of this target gene regulated by IGF2BP1
Cell Line A549 cell line Homo sapiens
Treatment: IGF2BP1 knockout A549 cells
Control: Wild type A549 cells
 GSE146546
Regulation
logFC: 6.39E-01
p-value: 1.76E-04
More Results Click to View More RNA-seq Results
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary METTL3 potentiates resistance to cisplatin through m6A modification of Transcription factor AP-2 gamma (TFAP2C) in seminoma. Enhanced stability of TFAP2C mRNA promoted seminoma cell survival under cisplatin treatment burden probably through up-regulation of DNA repair-related genes. IGF2BP1 binds to TFAP2C and enhances TFAP2C mRNA stability.
Target Regulation Up regulation
Responsed Disease Testicular cancer ICD-11: 2C80
 Disease Info 
Responsed Drug Cisplatin Approved
 Drug Info 
Pathway Response Nucleotide excision repair hsa03420
Cell Process DNA repair
In-vitro Model TCam-2 Testicular seminoma Homo sapiens CVCL_T012
In-vivo Model Male mice were subcutaneously injected with tumour cells near the limbs to establish xenografts (1 × 106/mouse, 0.2 mL for each injection site; METTL3-overexpressing TCam-2/CDDP cells were inoculated once at the initial time and IGF2BP1-inhibited TCam-2/CDDP cells were inoculated every 3 days).
Testicular cancer [ICD-11: 2C80]
 Disease Info 
In total 2 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary METTL3 potentiates resistance to cisplatin through m6A modification of Transcription factor AP-2 gamma (TFAP2C) in seminoma. Enhanced stability of TFAP2C mRNA promoted seminoma cell survival under cisplatin treatment burden probably through up-regulation of DNA repair-related genes. IGF2BP1 binds to TFAP2C and enhances TFAP2C mRNA stability.
Responsed Disease Testicular cancer [ICD-11: 2C80]
Target Regulator Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) READER
 Regulator Info 
Target Regulation Up regulation
Responsed Drug Cisplatin Approved
 Drug Info 
Pathway Response Nucleotide excision repair hsa03420
Cell Process DNA repair
In-vitro Model TCam-2 Testicular seminoma Homo sapiens CVCL_T012
In-vivo Model Male mice were subcutaneously injected with tumour cells near the limbs to establish xenografts (1 × 106/mouse, 0.2 mL for each injection site; METTL3-overexpressing TCam-2/CDDP cells were inoculated once at the initial time and IGF2BP1-inhibited TCam-2/CDDP cells were inoculated every 3 days).
Experiment 2 Reporting the m6A-centered Disease Response [1]
Response Summary METTL3 potentiates resistance to cisplatin through m6A modification of Transcription factor AP-2 gamma (TFAP2C) in seminoma. Enhanced stability of TFAP2C mRNA promoted seminoma cell survival under cisplatin treatment burden probably through up-regulation of DNA repair-related genes. IGF2BP1 binds to TFAP2C and enhances TFAP2C mRNA stability.
Responsed Disease Testicular cancer [ICD-11: 2C80]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
Responsed Drug Cisplatin Approved
 Drug Info 
Pathway Response Nucleotide excision repair hsa03420
Cell Process DNA repair
In-vitro Model TCam-2 Testicular seminoma Homo sapiens CVCL_T012
In-vivo Model Male mice were subcutaneously injected with tumour cells near the limbs to establish xenografts (1 × 106/mouse, 0.2 mL for each injection site; METTL3-overexpressing TCam-2/CDDP cells were inoculated once at the initial time and IGF2BP1-inhibited TCam-2/CDDP cells were inoculated every 3 days).
Cisplatin [Approved]
 Drug Info 
In total 2 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response [1]
Response Summary METTL3 potentiates resistance to cisplatin through m6A modification of Transcription factor AP-2 gamma (TFAP2C) in seminoma. Enhanced stability of TFAP2C mRNA promoted seminoma cell survival under cisplatin treatment burden probably through up-regulation of DNA repair-related genes. IGF2BP1 binds to TFAP2C and enhances TFAP2C mRNA stability.
Target Regulator Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) READER
 Regulator Info 
Target Regulation Up regulation
Responsed Disease Testicular cancer ICD-11: 2C80
 Disease Info 
Pathway Response Nucleotide excision repair hsa03420
Cell Process DNA repair
In-vitro Model TCam-2 Testicular seminoma Homo sapiens CVCL_T012
In-vivo Model Male mice were subcutaneously injected with tumour cells near the limbs to establish xenografts (1 × 106/mouse, 0.2 mL for each injection site; METTL3-overexpressing TCam-2/CDDP cells were inoculated once at the initial time and IGF2BP1-inhibited TCam-2/CDDP cells were inoculated every 3 days).
Experiment 2 Reporting the m6A-centered Drug Response [1]
Response Summary METTL3 potentiates resistance to cisplatin through m6A modification of Transcription factor AP-2 gamma (TFAP2C) in seminoma. Enhanced stability of TFAP2C mRNA promoted seminoma cell survival under cisplatin treatment burden probably through up-regulation of DNA repair-related genes. IGF2BP1 binds to TFAP2C and enhances TFAP2C mRNA stability.
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
Responsed Disease Testicular cancer ICD-11: 2C80
 Disease Info 
Pathway Response Nucleotide excision repair hsa03420
Cell Process DNA repair
In-vitro Model TCam-2 Testicular seminoma Homo sapiens CVCL_T012
In-vivo Model Male mice were subcutaneously injected with tumour cells near the limbs to establish xenografts (1 × 106/mouse, 0.2 mL for each injection site; METTL3-overexpressing TCam-2/CDDP cells were inoculated once at the initial time and IGF2BP1-inhibited TCam-2/CDDP cells were inoculated every 3 days).
References
Ref 1 METTL3 potentiates resistance to cisplatin through m(6) A modification of TFAP2C in seminoma. J Cell Mol Med. 2020 Oct;24(19):11366-11380. doi: 10.1111/jcmm.15738. Epub 2020 Aug 28.